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Abstract
Objective—The aim of the study was to examine the rates and predictors of treatment modification
following combination antiretroviral therapy (cART) failure in Asian patients with HIV enrolled in
the TREAT Asia HIV Observational Database (TAHOD).
Methods—Treatment failure (immunological, virological and clinical) was defined by World
Health Organization criteria. Countries were categorized as high or low income by World Bank
criteria.
Results—Among 2446 patients who initiated cART, 447 were documented to have developed
treatment failure over 5697 person-years (7.8 per 100 person-years). A total of 253 patients changed
at least one drug after failure (51.6 per 100 person-years). There was no difference between patients
from high- and low-income countries [adjusted hazard ratio (HR) 1.02; P = 0.891]. Advanced disease
stage [Centers for Disease Control and Prevention (CDC) category C vs. A; adjusted HR 1.38, P =
0.040], a lower CD4 count (≥ 51 cells/μL vs. ≤ 50 cells/μL; adjusted HR 0.61, P = 0.022) and a higher
HIV viral load (≥ 400 HIV-1 RNA copies/mL vs. < 400 copies/mL; adjusted HR 2.69, P < 0.001)
were associated with a higher rate of treatment modification after failure. Compared with patients
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from low-income countries, patients from high-income countries were more likely to change two or
more drugs (67% vs. 49%; P = 0.009) and to change to a protease-inhibitor-containing regimen (48%
vs. 16%; P< 0.001).
Conclusions—In a cohort of Asian patients with HIV infection, nearly half remained on the failing
regimen in the first year following documented treatment failure. This deferred modification is likely
to have negative implications for accumulation of drug resistance and response to second-line
treatment. There is a need to scale up the availability of second-line regimens and virological
monitoring in this region.
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Introduction
The World Health Organization (WHO) estimated that about 3 million people were receiving
antiretroviral therapy by the end of 2007, nearly 950 000 more compared with the year before
and a 7.5-fold increase over the past 4 years [1].
The aim of antiretroviral treatment is to prolong life by suppression of viral replication to below
the level of detection with standard assays in plasma, leading to immune reconstitution [2].
The decision to modify a treatment regimen when treatment failure develops is crucial to
prevent the accumulation of drug resistance and preserve any remaining activity within the
nucleoside (nucleotide) reverse transcriptase inhibitor [N(t)RTI] class, thereby ensuring the
maximal effectiveness of second-line therapy, as agents from N(t)RTIs are recommended in
combination with a boosted protease inhibitor [3–5].
There are few data on antiretroviral change following treatment failure that can inform
decisions in HIV-infected patients in the Asia and Pacific region, where many settings are
resource-limited and diagnostic and resistance testing is not routinely available. In addition,
there is limited access to effective new antiretroviral regimens in many developing countries
in the Asia and Pacific region [6,7].
The objective of this paper was to examine the rates and predictors of treatment modification
following documented treatment failure in Asian patients, using data from the TREAT Asia
HIV Observational Database (TAHOD).
Methods
TAHOD is a collaborative observational cohort study involving 17 participating clinical sites
in the Asia and Pacific region (see Acknowledgements). Detailed methods are published
elsewhere [8]; briefly, each site recruited approximately 200 patients, both treated and
untreated with antiretroviral therapy; recruitment was based on a consecutive series of patients
regularly attending a given clinical site from a particular start-up time; Ethics Committee
approval for the study was obtained from the University of New South Wales Human Research
Ethics Committee and from a local ethics committee for each participating TAHOD site.
The following data were collected: (i) patient demographics and baseline data: date of the
clinical visit, age, sex, ethnicity, exposure category, date of first positive HIV test, HIV-1
subtype, and date and result of hepatitis B, hepatitis C and syphilis serology; (ii) stage of
disease: CD4 and CD8 cell count, HIV viral load, prior and new AIDS-defining illnesses, and
date and cause of death; (iii) treatment history: prior and current prescribed antiretro-viral
treatments, reason for treatment changes and prophylactic treatments for opportunistic
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infections. The reasons for treatment change were coded as treatment failure, clinical
progression or hospitalization, patient decision or request, compliance difficulties, drug
interaction, adverse events and other reasons.
TAHOD patients were included in the analysis if they were naïve to antiretroviral treatment,
and had initiated treatment with triple or more combination therapy since 1996. Treatment
failure was defined using WHO guidelines for antiretroviral therapy for adults and adolescents
[3]. The guidelines include definitions according to immunological, virological and clinical
status to guide modification of treatment:
• CD4 cell count: after 6 months of therapy, a CD4 cell count below the pretreatment
level, or a 50% decline from the on-treatment peak CD4 cell count, or three
consecutive CD4 counts below 100 cells/μL;
• HIV viral load: after 6 months of therapy, an HIV viral load test result of >10 000
copies/mL;
• Clinical progression: after 6 months of therapy, development of an AIDS-defining
illness.
The date of treatment failure was identified from the database according to the WHO
guidelines. The earliest failure was included for patients with more than one type of failure
during treatment.
TAHOD sites were grouped into low (low and lower-middle) and high (upper-middle and
upper) income categories according to the gross national income per capita from The World
Bank [9].
Modification of antiretroviral treatment following treatment failure was defined as a change
to (adding, stopping or substituting) at least one drug in the treatment combination received at
the time at which treatment failure was identified. A treatment modification with a duration of
14 days or less was ignored. TAHOD sites were asked to provide reasons when an antiretroviral
drug was stopped, using a standard format specified in the TAHOD protocol. The reasons
include treatment failure, clinical progression/hospitalization, patient decision/request,
compliance difficulties, drug interaction, adverse event and other.
Follow-up was censored at the date of treatment change or the last clinical visit. Time to
treatment modification was determined by univariate and multivariate survival analysis
methods (Kaplan–Meier and Cox proportional hazards models). Predictors associated with
modification after treatment failure were assessed using multivariate Cox proportional hazards
models with a forward stepwise approach. The final multivariate model was stratified by site
and included only covariates that remained significant at the 0.05 level (two-sided).
Nonsignificant variables were presented and adjusted for final multivariate models. Analysis
was performed using the statistical package STATA 10 for Windows (StataCorp, College
Station, TX).
Results
Up to March 2007, there were 2446 TAHOD patients who were treatment-naïve and initiated
combination antiretroviral therapy (cART) regimens after 1996. There were 16 patients who
died after treatment initiation and before a treatment failure was identified; of these, five
patients died from AIDS-related causes, seven from non-AIDS-related causes and four from
unknown causes. The median treatment period was 1.97 years [interquartile range (IQR) 0.75–
3.55 years]. During the treatment period, the median number of CD4 tests was 4 (IQR 2–8),
the median interval between each CD4 test was 147 days (IQR 105–200 days), the median
Zhou et al. Page 3
HIV Med. Author manuscript; available in PMC 2010 May 4.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
number of HIV viral load tests was also 4 (IQR 2–7), and the median interval between each
viral load test was 168 days (IQR 112–231 days). The proportion of patients having four or
more CD4 tests and/or viral tests varied considerably across the TAHOD sites (from < 10% to
over 80%).
A total of 447 patients were identified with at least one type of treatment failure [Table 1; rate
of treatment failure 7.85 per 100 person-years; 95% confidence interval (CI) 7.15–8.61]. There
were 277 patients with immunological failure (after 6 months of therapy, 151 with a CD4 cell
count below the pretreatment level; 157 with a 50% decline from the on-treatment peak CD4
cell count; and 36 with three consecutive CD4 counts below 100 cells/μL), 158 patients with
virological failure (>10 000 copies/mL after 6 months of therapy), and 116 patients with an
AIDS-defining illness diagnosed after 6 months of therapy. For a patient with multiple
documented failures, the earliest failure was identified for analysis in this paper (242 with
immunological failure, 112 with virological failure and 93 with disease progression; a total of
447 patients).
Following treatment failure, a total of 253 patients had a treatment modification after failure,
of whom 44 had their treatment modified on the same day on which treatment failure was
identified. During a median follow-up time of 0.64 years (IQR 0.15–1.61 years), a further 209
patients changed at least one drug. The rate of treatment modification after failure was 51.6
per 100 person-years (95% CI 45.6–58.4). Of the 194 patients whose treatment was not
modified after treatment failure, three patients died, and 18 patients were lost to follow-up.
Time to treatment modification after failure, by country income category and by type of
treatment failure, is shown in Figure 1. The rate of treatment modification was similar in
patients from high- and low-income countries. However, the rate of modification was higher
in patients with a virological failure than in patients with either immunological failure or
clinical progression. At the end of the first year following failure, approximately 40% of
patients with virological failure remained on the previous regimen, compared with over 60%
of patients with either immunological failure or clinical progression.
Table 2 shows the factors associated with time to antiretroviral treatment modification after
treatment failure by univariate and multivariate Cox proportional hazards models. In the final
model (stratified by TAHOD sites) the factors independently associated with treatment
modification after failure included CDC classification, CD4 cell count and HIV viral load, all
at the time of treatment failure: compared with patients who were in CDC category A, patients
in category C were more likely to have a modification of treatment [hazard ratio (HR) 1.38,
CI 1.01–1.87, P = 0.040]; compared with patients with a CD4 count ≤ 50 cells/μL at the time
of failure, patients with a CD4 count ≥ 51 cells/μL were less likely have their treatment modified
(HR 0.61, CI 0.40–0.93, P = 0.022); lastly, compared with patients with an HIV load < 400
copies/mL at the time of failure, patients with an HIV viral load ≥ 400 copies/mL or those with
an unavailable HIV load were more likely to have their treatment modified (HR 2.69, CI 1.90–
3.81, P< 0.001; HR 1.74, CI 1.14–2.66, P = 0.010, respectively).
Overall, there was little difference between high- and low-income sites in terms of time to
treatment modification after failure. However, from Figure 1 it appears that there may be some
divergence after 2 years. We therefore performed an additional stratified analysis, comparing
high- and low-income countries in the first 2 years, and more than 2 years, after failure. In the
first 2 years, the rate of modification was similar in low- and high-income countries (low- vs.
high-income, HR 1.08, 95% CI 0.80–1.46, P = 0.632). In follow-up after 2 years, the rate was
lower in patients from low-income countries; however, possibly because of the small numbers
of patients with up to 2 years of follow-up (90 in total), the difference was not statistically
significant (low vs. high, HR 0.49, 95% CI 0.23–1.03, P = 0.059). Sensitivity analyses were
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also performed on patients who started treatment in or after 2003; the results were similar to
those obtained when all eligible patients were included (data not shown).
When their treatment was modified, 24 (10% of 253) patients had one or more drugs added,
92 (36%) had one drug changed and 137 (54%) had two or more drugs changed. Although the
rates of treatment modification were similar in patients from high- and low-income countries
(adjusted HR 1.02, P = 0.891), patients from high-income countries were more likely to have
two or more drugs changed (67% vs. 49%, P = 0.009) and to change to a protease-inhibitor-
based regimen (48% vs. 16%, P < 0.001).
Figure 2 shows the reported reasons for stopping a drug when treatment was modified,
summarized according to country income category, type of treatment failure and time from
treatment failure. Treatment failure was only one of the reasons for modifying drugs (25% of
all reported reasons). Patients from high-income countries were more likely to report treatment
failure as the reason for stopping a drug than those from low-income countries (32% vs. 21%,
P = 0.003). More drugs were reported to be stopped because of treatment failure following an
identified virological failure than following immunological failure and clinical progression
(39% vs. 21% and 3%, respectively; P< 0.001). Treatment failure as the reason for stopping a
drug was reported at similar rates in the first 90 days, at 91–180 days and at 181 days or more
from the documented treatment failure (26%, 33% and 21%, respectively; P = 0.125).
Discussion
In this study, we found that among a cohort of HIV-infected patients in the Asia and Pacific
region, in the first year following documented treatment failure, nearly half remained on the
same failing regimen. Advanced disease stage (CDC category C), lower CD4 cell count and
higher HIV viral load were associated with a higher rate of treatment modification after failure.
Compared with patients from low-income countries, patients from high-income countries were
more likely to have two or more drugs changed and to change to a protease-inhibitor-based
regimen when their treatment was modified after failure.
Definitions of treatment failure vary in the guidelines from different countries and regions
[3,10–12]. The WHO guidelines include definitions according to immunological, virological
and clinical status to guide modification of treatment, taking into consideration the fact that
sophisticated laboratory investigations, including baseline and longitudinal CD4 and viral load
measurements, are not always available and are likely to remain limited in the short- to mid-
term for a number of reasons, including cost and capacity. It is perhaps not surprising in our
study that the TAHOD patients from sites in high-income countries had more drugs to change
and more access to protease-inhibitor-based regimens. Previous analysis in TAHOD [13]
showed that drug availability influences treatment prescription patterns.
According to the WHO guidelines [3], when HIV viral load testing is not available, patients
with immunological failure are not recommended to switch treatment if they have WHO stage
2 or 3 disease (i.e. not stage 4). The WHO guidelines also recommend that premature
modification from first-line to second-line treatment should be avoided, with the assumption
that the provision of second-line drugs is in the public sector and the availability is usually
limited. This may mean that clinicians are not willing to modify the regimen immediately in
the presence of treatment failure if virological failure cannot be confirmed. The higher rate of
modification after virological failure in TAHOD than after immunological and clinical failure
lends support to this interpretation. However, there remain a large proportion of patients (nearly
40%) who continue the same failing regimen 1 year after identification of virological failure,
which is probably a result of the limited treatment options available. We found that advanced
disease stage (CDC category C), a lower CD4 cell count and a higher HIV viral load were
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associated with a higher rate of treatment modification after failure. This probably indicates
that the clinicians in TAHOD clinics were prioritizing treatment options to those failed patients
with more advanced immune deficiency as a result of limited resources.
In a case note and questionnaire-based audit in the United Kingdom [14], after virological
failure (defined as a viral load rebound from undetectable, not reaching an undetectable level,
and/or an increase in viral load), change of therapy was found to occur in < 4 months in 43%
of patients, in 4–6 months in 20% of patients and in >6 months in 34% of patients. Of the
patients with virological failure who had their treatment modified, 48% switched to three or
more new drugs, 32% to two new drugs and 20% to one new drug. In another study from the
United Kingdom, Collaborative HIV Cohort (CHIC) [15], only one-third of patients remained
on a failing regimen for more than 6 months after virological rebound of >400 copies/mL, and
the proportions were 20% and 9% at 1 and 2 years after rebound, respectively. The rate of
treatment modification after treatment failure in TAHOD patients is clearly slower than that
seen in the United Kingdom, where routine HIV viral load tests and second-line treatment
options are readily available.
Treatment failure was only one of the reported reasons for modification of treatment after
identification of failure. These clinical data provide an insight into clinical practice with regard
to HIV treatment and care in the Asia and Pacific region. Adverse events were reported to be
a major reason for treatment change after initiation, both in TAHOD [13,16] and in other
cohorts [14]. This suggests that the TAHOD clinicians are aware of the adverse effects
associated with cART and are ready to change treatment if toxicity is present. The difference
in the proportions of reported reasons for stopping a drug between high- and low-income
countries may reflect differences in the availability of clinical monitoring, treatment and care,
and clinical expertise in the Asia and Pacific region.
One systematic review [17] showed that there is insufficient evidence to evaluate second-line
therapies in patients with HIV infection who fail first-line treatment with nonnucleoside reverse
transcriptase inhibitor (NNRTI) + N(t)RTI combinations. Individualized treatment decisions
are recommended to be based on patient treatment history, appropriate agents for inclusion and
HIV drug resistance testing. A number of new agents, including some in new antiretroviral
classes [for instance CCR5 inhibitors (e.g. maraviroc) and integrase strand transfer inhibitors
(e.g. InSTI and raltegravir)], have recently been approved, raising the possibility that second-
line therapy could be constructed from two agents from two drug classes to which the patient
is naïve (e.g. a boosted protease inhibitor plus InSTI). Such a strategy would remove the need
for genotypic resistance testing and would be more consistent with the simplified, public health
approach to antiretroviral management recommended for use in resource-limited settings
[18]. There is a need to design randomized controlled trials to determine optimal second-line
therapy strategies for both resource-rich and resource-limited settings.
Failure of first-line antiretroviral therapy is inevitable sooner or later in a proportion of patients.
Access to second-line antiretroviral therapy regimens in developing countries is limited by the
expense of second-line treatment as a result of the inclusion of protease inhibitors [7]; the cost
of a protease-inhibitor-containing second-line regimen is in the order of five times the cost of
the cheapest available fixed-dose generic NNRTI + N(t)RTI combination. It was estimated
that in India, by 2, 3 and 3.5 years after 2007, there will be 16 000, 35 000 and 51000 patients,
respectively, who are currently receiving antiretroviral therapy and who are likely to require
second-line treatment [19].
In resource-limited settings where second-line treatment options are limited, and where
preservation of activity in the N(t)RTI class may be critical to the success of second-line
therapy, it is crucial to prevent HIV drug resistance. Early detection of virological failure may
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provide more options and better treatment outcomes [20]. Orrell et al. [21] also showed that
regular follow-up with viral load tests and adherence intervention by a peer counsellor is
associated with a low rate of treatment failure, which leads to the retention of individuals on
first-line therapy and the conservation of more expensive second-line treatment options. With
the increasing need for second-line regimens, more effort should be made urgently to ensure
HIV viral load testing becomes affordable, simple and easy to use in routine clinical practice,
even in resource-limited settings [22,23]
Several limitations should be considered in interpreting the results in this paper. One recent
study [24] showed that WHO clinical and CD4 criteria have poor sensitivity and specificity in
detecting virological failure. The observational nature of TAHOD means that treatment failure
was identified depending on the local clinic approach, which would differ across the TAHOD
sites. The frequency of CD4 testing and HIV viral load measurement varies significantly across
the TAHOD sites, and, in particular, there is no systematic monitoring of CD4 and/or HIV
viral load testing at TAHOD sites according to a standardized visit schedule. These issues
relating to differences in monitoring among sites may result in underestimation of the overall
rate of treatment failure and hence actual treatment modification may have been deferred for
even longer times. However, the main objective of this paper was to examine the time from
any documented treatment failure to any treatment change. The failures we analysed were
documented treatment failures, and so might be expected to give an indication of real-life
clinical practice in this region. In addition, adherence data are not collected in TAHOD, and it
is possible that in the presence of failure another reason for the delay in treatment switch may
be that clinicians were trying to improve adherence to the existing regimen before definitively
declaring treatment failure. Furthermore, as TAHOD participating sites are generally urban
referral centres, and each site recruits approximately 200 patients who are judged to have a
reasonably good prospect of long-term follow-up, TAHOD patients may not be entirely
representative of HIV-infected patients in the Asia and Pacific region. Finally, a more thorough
analysis would include the survival outcome of treatment change after treatment failure was
identified. However, because of the limited number and follow-up of patients who have
treatment modification after failure, this analysis is currently underpowered, and a further
analysis will be performed when TAHOD has more follow-up data.
Deferred modification of regimen following treatment failure in many Asian countries
following rapid scale-up of antiretroviral treatment is likely to have negative implications for
accumulation of drug resistance and response to second-line treatment which incorporates
agents from the N(t)RTI class. There is a need to scale up the availability of agents for use in
second-line regimens and implement the use of virological monitoring in this region.
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Fig. 1.
Time to treatment modification after treatment failure, by country income category and type
of treatment failure. cART, combination antiretroviral therapy.
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Fig. 2.
Reported reasons for stopping a drug when treatment was modified. (a) all drugs; (b) by country
income category (b-1, low-income; b-2, high-income); (c) by type of treatment failure (c-1,
immunological failure; c-2, virological failure; c-3, clinical progression), (d) by time from
treatment failure (d-1, up to 90 days; d-2, 91–180 days; d-3, 181 days or more).
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Table 1
Patient characteristics (n = 447)
n (%)
Sex
 Male 342 (77)
 Female 105 (23)
Age at time of failure (years)
 ≤30 119 (27)
 31–40 203 (45)
 41 + 125 (28)
Reported mode of infection
 Heterosexual contact 288 (65)
 Homosexual contact 94 (21)
 Injecting drug use 24 (5)
 Blood products 32 (7)
 Other/unknown 9 (2)
CDC classification at time of failure
 Category A 173 (39)
 Category B 39 (9)
 Category C 235 (52)
Country income category
 Low-income 323 (72)
 High-income 124 (28)
CD4 count (cells/μL) at time of failure
 ≤50 39 (9)
 51 + 349 (78)
  51–100 46 (10)
  101–200 108 (24)
  201–300 91 (20)
  301 + 104 (23)
 Not tested 59 (13)
HIV viral load (copies/mL) at time of failure
 <400 121 (27)
 400 or more 145 (33)
  400–10 000 13 (3)
  10 000 + 132 (30)
 Not tested 181 (40)
Antiretroviral treatment* at time of failure
 3 + (NRTI +NNRTI – PI) 318 (71)
 3 +(NRTI – NNRTI + PI) 100 (22)
 Others 29 (7)
Type of treatment failure
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n (%)
 Immunological 242 (54)
 Virological 112 (25)
 Clinical 93 (21)
*
Antiretroviral treatment:
3 + (NRTI + NNRTI – PI), combination of three or more drugs including NRTI and NNRTI but not PI.
3 + (NRTI – NNRTI + PI), combination of three or more drugs including NRTI and PI but not NNRTI.
CDC, Centers for Disease Control and Prevention; PI, protease inhibitor; NRTI, nucleoside (nucleotide) reverse transcriptase inhibitor; NNRTI,
nonnucleoside reverse transcriptase inhibitor.
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